Oral-ATO for TP53-mutated Myeloid Malignancies

This is an open-label, phase 2 study of oral arsenic trioxide (Arsenol ®) in combination with ascorbic acid and investigator choice of low-intensity therapy in patients with previously untreated or relapse/refractory TP53-mutated acute myeloid leukemia (AML), myelodysplastic neoplasm (MDS), chronic myelomonocytic leukemia (CMML).

Trial Details

NCT ID
NCT06778187
Phase
PHASE2
Sponsor
The University of Hong Kong
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Oral arsenic trioxide
Locations (sample)
  • Hong Kong, Hong Kong|22.27832,114.17469

Key Eligibility Criteria

  • Willing and able to provide informed consent
  • Age ≥18 years
  • Diagnosis of acute myeloid leukemia (AML), myelodysplastic neoplasm (MDS) or chronic myelonocytic leukaemia (CMML) by World Health Organization (WH…
  • Presence of TP53 mutation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →